1) in vitro release mechanism
体外释药机制
1.
Objective To study the formulation and preparation factors influencing in vitro release mechanism of drug fromκ-carrageenan/konjac glucomannan hydrophilic matrix tablets.
目的研究影响盐酸青藤碱κ-卡拉胶/魔芋胶骨架片体外释药机制的处方和工艺因素。
2) Drug release mechanism in vitro
体外释药机理
3) in vitro release
体外释药
1.
Preparation and in vitro release of poly(DL-lactide) microspheres containing tinidazole;
替硝唑聚乳酸微球的制备及其体外释药性能
2.
Study on preparation and in vitro release of 5-fluorouracil loaded polylactide-co-glycolide-co-poly(ethylene glycol) nanoparticles;
PEG-PLGA载5-FU纳米缓释微球的制备及体外释药研究
3.
Formulation optimization and the in vitro release characteristics of Fuyankang Dispersible Tablets;
妇炎康分散片的辅料处方优化及体外释药特性
4) release in vitro
体外释药
1.
Affecting factor of the diclofenac potassium release in vitro from hydroxypopylmethyl cell ulose tablets;
双氯芬酸钾羟丙基甲基纤维素骨架片体外释药的影响因素
2.
Preparation of Nanoliposome Coated with Hydroxycamptothecin and Study on Release in vitro;
羟基喜树碱包衣纳米脂质体的制备及体外释药研究
3.
Preparation of Xionggui nasal sprays and its evaluation in release in vitro and absorption in vivo;
芎归鼻用喷雾剂的制备及其体外释药与在体吸收特性评析
5) In vitro drug release
体外释药
1.
Effects of pH and ionic strength of release media on in vitro drug released from carboxymethyl konjac glucomannan pellets;
释放介质pH和离子强度对羧甲基魔芋胶小丸体外释药的影响
2.
OBJECTIVE To prepare clindamycin hydrochloride microcapsule by means of intra liquid desiccation and to determine its in vitro drug release.
目的 采用液中干燥法制备盐酸克林霉素微囊 ,并考察其体外释药特性。
3.
And factors influencing in vitro drug release rate of the matrix tablets were studied.
以茶碱为模型药物，制备了黄原胶亲水性骨架片，研究了体外释药的影响因素。
6) drug release in vitro
体外释药
1.
Study on preparation and drug release in vitro of temozolomide-chitosan microspheres;
替莫唑胺壳聚糖缓释微球的制备及体外释药特性
2.
Influencing factors of ophiopogonin enteric microsphere' drug release in vitro
麦冬皂苷肠溶微球体外释药影响因素研究
3.
The drug content was examined by Lowry methods, and the drug loading, encapsulation efficiency, and drug release in vitro were calculated.
方法 :用乳化交联法制备胸腺肽明胶微球 ,正交设计法筛选其最佳制备工艺 ,Lowry法测定药物的含量 ,计算微球的载药量、包封率及体外释药量。
补充资料：抗真菌药和抗立克次氏体药
抗真菌药和抗立克次氏体药
Chemotherapeutics, Antimycotic and Antirickettsial
kans抗真菌药和抗立克次氏体药第9卷 O }}(1)CICH之一C一CHZCI一-~甲~~~~~叫~~一~~~(2)CHaC00H FB了IJ ︸胜、!尸以.纵扮!F(48) OH lCICH:一C一CHZCIN=，、 1，1 NH尸丫r，一一三之~、汗尸Na月，DMF F(49)(11) :HzN~3。:。您丫督自气丛立竺竺自护、-跳沪/、‘犷HCOH、屯/卜‘2 (51)(52) 。之丫⑧ 坐助OH(‘2，(53) HCI-~~，~~~~~~，..~ 一H20‘HCI(90)侧 月F C.\H一\l尸n下.C上z、丫F H C 一 N =‘ N 1.1七(47) 氟康哇口服吸收快而完全，半衰期长(22~32h)体内分布均匀，能很好的透过血脑屏障，并渗透到脑脊液内阳〕。口服100mg后，脑脊液平均浓度为血浆浓度的0.58一0.89倍。70%原药由肾脏排除。 大多数病人对氟康哇耐受良好哪〕。常见的副作用为头痛、恶心、疲劳、发热、浮肿、出疹、腹部不适及转氨酶升高。但发生率小于5环，极少数病人出现血小板减少，停药后即恢复。·2.8.烯丙胺类 1981年发现蔡替芬(haftifine)(s0)具有较高的广谱抗真菌活性。由于其优良的抗真菌活性，新颖的结构特点，很快引起了人们的重视，通过对其结构改造和抗菌活性的研究，发现了活性高、毒性低的衍生物特比禁芬(terbinafine)(‘oa)和丁禁芬(botenafine)(乐ob)。活性最大，最低抑菌浓度(Mlc)为。.01一0.2哆/ml，对申克氏抱子丝菌和曲霉属真菌次之，Mlc分别为0.8一1.5限/耐和0.8~12.5阳/而。禁替芬的体外抗皮肤真菌活性明显优于咪哇类抗真菌药，而与托蔡醋(发癣退)和灰黄霉素相似。 蔡替芬对真菌细胞超微结构有影响，还干扰真菌细胞的脂质代谢，故有杀菌作用。在作用机理上蔡替芬与氮哇类药物一样，都是抑制麦角幽醇的生物合成，但作用部位二者不同，禁替芬是角拨烯的环氧化酶的特异性抑制剂。通过抑制角鳖烯的环氧化，使角盆烯蓄积和麦角幽醉缺乏，使真菌细胞膜的组成和通透性发生改变，导致杀菌作用[5，〕。 蔡替芬是一个高效低毒的外用抗真菌药，其疗效与克霉哇、美康哇、益康哇等外用抗真菌药相似。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条